Antiviral drugs work by targeting specific steps in a virus’s lifecycle, blocking the virus from copying itself or spreading to new cells. Unlike antibiotics, which can kill bacteria directly, antivirals face a unique challenge: viruses hijack your own cells to reproduce, so the drug has to disrupt the virus without destroying the cell it’s hiding in. This is why antivirals are harder to develop and why each one typically works against only one virus or a narrow family of viruses.
Why Antivirals Are Different From Antibiotics
Bacteria are independent living cells with their own machinery. Antibiotics exploit that independence by attacking structures like cell walls or bacterial protein factories that human cells don’t have. A single antibiotic can often treat many different bacterial infections because those structures are shared across species.
Viruses have no cell walls, no metabolism, and no machinery of their own. They’re essentially packets of genetic instructions that force your cells to do the manufacturing. That means an antiviral drug has to find something distinctly viral to interfere with, some enzyme or protein the virus brought along that your healthy cells don’t use. This is a much narrower target, which is why there are far more viruses than there are antiviral drugs to treat them.
The Viral Lifecycle: Where Drugs Can Strike
Every virus goes through the same basic sequence to reproduce. It attaches to a cell, gets inside, sheds its outer coat, forces the cell to copy its genetic material and build new viral proteins, assembles those components into new virus particles, and releases them to infect more cells. In theory, a drug could intervene at any of these stages. In practice, most clinically used antivirals target the replication stage, where the virus copies its genetic material, because the enzymes involved are distinctly viral and make clean targets.
Blocking the Front Door: Entry Inhibitors
Some antivirals stop a virus before it ever gets inside your cell. These drugs work in a few ways. One approach blocks the surface protein the virus uses to latch onto a cell receptor, like jamming a key so it can’t fit into a lock. Another approach targets the cell’s own receptor so the virus has nothing to grab onto. A third blocks the fusion process, where the virus’s outer membrane merges with the cell membrane to inject its contents inside.
HIV treatment provides the clearest examples. Maraviroc binds to a co-receptor on human immune cells called CCR5, physically blocking the virus from docking. Enfuvirtide, the first approved fusion inhibitor, is a small protein fragment that mimics part of the virus’s own fusion machinery, essentially wedging itself into the process and preventing the structural rearrangement the virus needs to merge with the cell. Ibalizumab, approved in 2018 for patients with drug-resistant HIV, takes yet another angle by binding to the CD4 receptor on immune cells near the site where the virus attaches.
Fake Building Blocks: Nucleoside Analogs
The largest and most widely used class of antivirals are nucleoside analogs, drugs that mimic the building blocks of DNA or RNA. When a virus copies its genetic material, it relies on a specialized enzyme (a polymerase) to string together nucleotides one by one, like beads on a chain. Nucleoside analogs look enough like real nucleotides that the viral polymerase picks them up and tries to use them, but they’re structurally flawed.
Once incorporated, the fake building block causes one of two problems. It can act as a chain terminator, missing the chemical “hook” needed to attach the next nucleotide. RNA synthesis simply stops mid-strand. Remdesivir, used against SARS-CoV-2, works this way. Alternatively, some analogs get incorporated but introduce so many errors into the viral genome that the resulting copies are riddled with mutations and can’t function, a strategy sometimes called lethal mutagenesis.
These drugs are technically inactive when you swallow them. Your own cellular enzymes have to convert them into their active form by adding phosphate groups, turning the “prodrug” into something the viral polymerase will accept. This activation step is another reason drug design in this space is so precise.
How Acyclovir Targets Only Infected Cells
Acyclovir, one of the most prescribed antivirals for herpes simplex and varicella zoster, is a textbook example of selective drug design. The drug is essentially inert in healthy cells because it needs a viral enzyme, thymidine kinase, to take the first activation step. Only cells already infected by the herpes virus contain this enzyme, so acyclovir gets converted to its active form almost exclusively where the virus is replicating. Infected cells accumulate 40 to 100 times more of the active compound than uninfected cells.
Once activated, acyclovir’s active form does double duty. It inhibits the viral DNA polymerase far more potently than it affects your cellular polymerases, and when the viral polymerase does incorporate it into a growing DNA strand, synthesis grinds to a halt. The polymerase binds tightly to the terminated strand and is effectively stuck. This selectivity is why acyclovir has extremely low toxicity for healthy tissue.
Cutting the Assembly Line: Protease Inhibitors
Many viruses, including HIV and the coronavirus behind COVID-19, produce their proteins as one long, non-functional chain called a polyprotein. A viral protease, a specialized cutting enzyme, then slices this chain at precise locations to release the individual proteins the virus needs to assemble into new particles. Without this processing step, the virus produces only useless, jumbled protein.
Protease inhibitors are designed to fit snugly into the active site of this cutting enzyme, preventing it from doing its job. Many are “peptidomimetics,” molecules shaped to resemble the protein chain the protease normally cuts, but engineered so they bind to the enzyme and won’t let go. HIV protease inhibitors were among the first developed, and they transformed HIV from a death sentence into a manageable chronic condition when combined with other drug classes.
Paxlovid, the oral COVID-19 treatment, uses the same principle. Its active ingredient targets the main protease of SARS-CoV-2, an enzyme essential for the virus to process its proteins and reproduce. The second component in the pill, ritonavir, doesn’t attack the virus at all. Instead, it blocks a liver enzyme that would otherwise break down the active drug too quickly, keeping effective drug levels in the bloodstream longer.
Trapping New Viruses: Neuraminidase Inhibitors
Oseltamivir (Tamiflu) and zanamivir take an entirely different approach. They don’t stop the flu virus from entering cells or copying itself. Instead, they prevent newly made virus particles from escaping the infected cell. Influenza viruses attach to a sugar called sialic acid on cell surfaces. After new viruses are assembled inside the cell, they’re still tethered to that sugar and can’t leave. Neuraminidase, a viral surface enzyme, clips the sialic acid tether and sets the new particles free to spread.
Block neuraminidase and the new viruses stay stuck. Infection is limited to roughly one round of replication, rarely enough to cause disease on its own. This is why timing matters so much with flu antivirals: the drug works by containing the spread within your respiratory tract, not by clearing virus that’s already everywhere.
Why Timing Matters
Antivirals are most effective when taken early, before the virus has spread widely through your body. For influenza, treatment within 48 hours of symptom onset is the standard window. For COVID-19 antivirals like Paxlovid, the recommended window is within 5 days of symptom onset. Starting treatment after these windows can still offer some benefit in certain cases, but the drugs have less virus to contain and more damage has already been done.
This timing requirement exists because of how antivirals work: they slow or stop viral replication, giving your immune system time to catch up and clear the infection. They don’t instantly kill every virus particle already present. The earlier you limit replication, the less work your immune system has to do.
How Viruses Develop Resistance
Viruses mutate constantly as they replicate, and some mutations happen to change the shape of the exact enzyme a drug targets. If the drug can no longer bind effectively, that mutant virus has a survival advantage and becomes the dominant strain in the patient’s body.
The patterns of resistance depend on the virus and the drug. Herpes viruses most commonly develop resistance to acyclovir through mutations in their thymidine kinase gene, the very enzyme the drug depends on for activation. These mutations often involve small insertions or deletions in repetitive stretches of the genetic code, causing the enzyme to lose function entirely. Without thymidine kinase, acyclovir never gets activated, and the drug becomes useless. Hepatitis B develops resistance through mutations in its polymerase gene that alter the drug-binding site. High-level resistance to the drug lamivudine, for example, typically involves a specific mutation in a critical region of the polymerase called the YMDD motif.
This is why combination therapy, using multiple drugs that hit different targets simultaneously, is standard for HIV and hepatitis treatment. A virus might develop a mutation that defeats one drug, but the odds of simultaneously developing mutations against two or three drugs with different mechanisms are extremely low. It’s the same logic behind using multiple antibiotics for tuberculosis, though the biological details differ.